Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2025-02-04 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges about a scheduled Board of Directors meeting to consider and approve the unaudited financial results for the quarter ended December 31, 2024. It references SEBI Listing Obligations and Disclosure Requirements Regulations and mentions the trading window closure due to insider trading regulations. The document does not contain the financial results themselves but announces the upcoming approval and release of such results. The document length is short (1895 characters) and serves as a notification rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification of an upcoming event, not the Interim/Quarterly Report (IR) itself.
2025-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges about a scheduled Board of Directors meeting to consider and approve the unaudited financial results for the quarter ended December 31, 2024. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The document does not contain the financial results themselves but announces the upcoming approval and release of these results. The document length is short (1895 characters) and serves as a notice rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification of an upcoming event related to financial reporting, not the report itself.
2025-02-04 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official announcement informing about the change of name of the Registrar and Share Transfer Agent (RTA) of the company. It references Regulation 30 of SEBI Listing Regulations, which pertains to disclosure of material events. The document includes a certificate of incorporation reflecting the name change of the RTA. There are no financial statements, management discussion, or detailed financial data. The document is relatively short (3947 characters) and serves as a notification to stock exchanges and stakeholders about the name change. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Interim Report, or Management Information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-01-04 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the closure of the trading window for directors and designated persons ahead of the announcement of unaudited financial results for the quarter ended December 31, 2024. It does not contain any financial data, results, or detailed report but is an announcement related to compliance and trading restrictions. The document length is only 1680 characters, indicating it is a brief regulatory announcement rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance notification.
2024-12-31 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges regarding the publication of newspaper advertisements as required under SEBI regulations. It mentions Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and encloses copies of advertisements published in newspapers. The document is only 1263 characters long and does not contain any financial data, detailed report content, or management discussion. It is an announcement about the publication of information rather than the information itself. Therefore, it fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-12-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.